Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

MoonLake Immunotherapeutics AG
Sponsor

MoonLake Immunotherapeutics AG

Dorfstrasse 29, 6300

About the sponsor

Clinical research in hidradenitis suppurativa focuses on moderate-to-severe disease, with attention to both symptom control and longer-term safety and tolerability outcomes.

  • Inflammatory skin disease
  • Moderate-to-severe hidradenitis suppurativa
  • Long-term safety

Trials in this area reflect interest in persistent cutaneous inflammation and treatment response over extended follow-up.

About Specializations

MoonLake Immunotherapeutics AG runs clinical trials in conditions such as Psoriatic arthropathy, Hidradenitis, Axial spondyloarthritis, Palmoplantar pustulosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Axial spondyloarthritis+1

Recruiting

Study on the Effects of Sonelokimab in Patients with Active Psoriatic Arthritis or Axial Spondyloarthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Hidradenitis

Not recruiting

Study on the Effects of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Palmoplantar pustulosis

Not recruiting

Study on the Effects of Sonelokimab for Patients with Moderate-to-Severe Palmoplantar Pustulosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Axial spondyloarthritis

Not recruiting

Study on the Effects of Sonelokimab for Patients with Active Axial Spondyloarthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.